Tharimmune (THAR) Competitors $1.90 +0.04 (+1.99%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$1.88 -0.02 (-1.05%) As of 02/21/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends THAR vs. HCWB, IPA, GOVX, NERV, TRIB, CING, CLRB, IMNN, CRVO, and BMRAShould you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include HCW Biologics (HCWB), ImmunoPrecise Antibodies (IPA), GeoVax Labs (GOVX), Minerva Neurosciences (NERV), Trinity Biotech (TRIB), Cingulate (CING), Cellectar Biosciences (CLRB), Imunon (IMNN), CervoMed (CRVO), and Biomerica (BMRA). These companies are all part of the "pharmaceutical products" industry. Tharimmune vs. HCW Biologics ImmunoPrecise Antibodies GeoVax Labs Minerva Neurosciences Trinity Biotech Cingulate Cellectar Biosciences Imunon CervoMed Biomerica HCW Biologics (NASDAQ:HCWB) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, community ranking, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership. Do analysts recommend HCWB or THAR? Tharimmune has a consensus price target of $17.00, suggesting a potential upside of 794.74%. Given Tharimmune's stronger consensus rating and higher possible upside, analysts plainly believe Tharimmune is more favorable than HCW Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCW Biologics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do institutionals and insiders hold more shares of HCWB or THAR? 3.0% of HCW Biologics shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 49.9% of HCW Biologics shares are owned by insiders. Comparatively, 2.4% of Tharimmune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings and valuation, HCWB or THAR? Tharimmune has lower revenue, but higher earnings than HCW Biologics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHCW Biologics$3.50M4.97-$24.99M-$1.00-0.39TharimmuneN/AN/A-$9.32MN/AN/A Does the media refer more to HCWB or THAR? In the previous week, Tharimmune had 1 more articles in the media than HCW Biologics. MarketBeat recorded 2 mentions for Tharimmune and 1 mentions for HCW Biologics. HCW Biologics' average media sentiment score of 0.00 equaled Tharimmune'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HCW Biologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tharimmune 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, HCWB or THAR? HCW Biologics has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Is HCWB or THAR more profitable? Tharimmune has a net margin of 0.00% compared to HCW Biologics' net margin of -1,067.82%. Tharimmune's return on equity of -167.63% beat HCW Biologics' return on equity.Company Net Margins Return on Equity Return on Assets HCW Biologics-1,067.82% -2,516.84% -132.95% Tharimmune N/A -167.63%-130.18% Does the MarketBeat Community favor HCWB or THAR? HCW Biologics received 4 more outperform votes than Tharimmune when rated by MarketBeat users. CompanyUnderperformOutperformHCW BiologicsOutperform Votes6100.00% Underperform VotesNo VotesTharimmuneOutperform Votes2100.00% Underperform VotesNo Votes SummaryTharimmune beats HCW Biologics on 10 of the 14 factors compared between the two stocks. Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THAR vs. The Competition Export to ExcelMetricTharimmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.60M$7.05B$5.82B$9.09BDividend YieldN/A2.76%4.77%3.84%P/E RatioN/A3.1618.9215.38Price / SalesN/A311.68453.2984.08Price / CashN/A67.2843.8437.22Price / Book0.016.717.644.65Net Income-$9.32M$138.11M$3.18B$245.69M7 Day PerformanceN/A-2.54%-1.95%-2.67%1 Month Performance-5.00%-2.00%-0.23%-2.16%1 Year Performance-66.58%-5.04%16.69%12.90% Tharimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THARTharimmune2.22 of 5 stars$1.90+2.0%$17.00+794.7%-66.2%$3.60MN/A0.002Upcoming EarningsNews CoverageHCWBHCW Biologics0.2584 of 5 stars$0.39-8.7%N/A-65.5%$14.56M$2.84M-0.3940IPAImmunoPrecise Antibodies2.9808 of 5 stars$0.47-1.4%$5.00+959.3%-77.6%$14.54M$18.16M-0.6080News CoverageGOVXGeoVax Labs1.7314 of 5 stars$1.54-1.5%$14.20+824.1%-24.9%$14.50M$3.09M0.0010NERVMinerva Neurosciences3.2149 of 5 stars$2.07-0.2%$5.00+142.1%-79.3%$14.43MN/A-4.699Analyst ForecastNews CoverageTRIBTrinity Biotech0.4042 of 5 stars$0.78+1.1%N/AN/A$14.08M$56.83M-0.35480CINGCingulate2.8604 of 5 stars$4.42+1.3%$16.00+262.4%+300.5%$14.08MN/A0.0020CLRBCellectar Biosciences1.979 of 5 stars$0.30-4.3%$17.67+5,788.9%-90.4%$13.78MN/A-0.1710Analyst ForecastIMNNImunon2.3242 of 5 stars$0.91+1.9%$20.50+2,157.7%+70.2%$13.17M$500,000.00-0.4830Analyst ForecastNews CoverageGap UpCRVOCervoMed3.5982 of 5 stars$2.13-2.8%$42.00+1,872.8%-84.3%$13.08M$7.14M0.004Analyst UpgradeNews CoverageBMRABiomerica0.489 of 5 stars$0.71-6.3%N/A-22.6%$12.91M$5.41M-2.0760Gap Up Related Companies and Tools Related Companies HCW Biologics Competitors ImmunoPrecise Antibodies Competitors GeoVax Labs Competitors Minerva Neurosciences Competitors Trinity Biotech Competitors Cingulate Competitors Cellectar Biosciences Competitors Imunon Competitors CervoMed Competitors Biomerica Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:THAR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
